stockrowBioCryst Pharmaceuticals, Inc. (BCRX) vs HUTCHMED (China) Limited Sponsored ADR (HCM)
- BioCryst Pharmaceuticals, Inc. BCRX 7.67 +0.52%
- HUTCHMED (China) Limited Sponsored ADR HCM 15.12 +6.48%
BioCryst Pharmaceuticals, Inc. and HUTCHMED (China) Limited Sponsored ADR are both Drug Manufacturers Specialty & Generic companies. HUTCHMED (China) Limited Sponsored ADR is the larger, with a market value of $2.5B against $2.0B — 1.3× the size. HUTCHMED (China) Limited Sponsored ADR grew revenue faster over the last twelve months: 245.2% against 60.3%. HUTCHMED (China) Limited Sponsored ADR has the higher net margin (−23.6% vs −37.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, BioCryst Pharmaceuticals, Inc. leads on 8 and HUTCHMED (China) Limited Sponsored ADR on 7.
Valuation
Profitability
| Metric | BCRX | HCM | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 97.89% | 44.40% | 53.51% |
| Operating margin | (30.10%) | 0.00% | 0.00% |
| Net margin | (37.41%) | (23.63%) | (2.45%) |
| Free cash flow margin | 38.11% | 0.00% | 0.00% |
| Return on equity | 91.60% | 0.00% | (0.80%) |
| Return on assets | (69.33%) | 0.00% | (1.67%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack